Breakthrough Demonstration of Single Cell Technology’s Antibody Discovery Process

San Jose, CA June 2, 2016

Single Cell Technology, Inc., (SCT) today announced their revolutionary antibody discovery technology correctly extracts the two DNA sequences of high affinity antibodies over 95% of the time. These results were confirmed when SCT’s antibodies were molecularly reconstructed by Lake Pharma, a leading contract research organization, and compared to an older process called ELISA. This breakthrough accomplishment, unique in the antibody discovery field, will encourage drug research and the discovery of new antibody thereapeutics.

Says Dr. Chun-Nan Chen, Founder and CEO of SCT, “Other brute force methods to match the light and heavy chains of high affinity antibodies have simply not kept up with the increasing demand for quality drug leads. And newer methods that appeared exciting at first produced disappointed results when investigated more closely. Fortunately SCT’s new and multiply patented approach is truly innovative – and it works! It’s a rare combination of “fast, cheap and good”. We anticipate many lives will be improved by SCT’s contribution to drug discovery.”


Single Cell Technology, Inc. (SCT) has pioneered a new approach to antibody discovery. Antibodies from secreting cells are rapidly screened against multiple molecules to measure their affinity and specificity and correctly paired mRNA from the cognate light and heavy chains are sequenced by Next Generation Sequencing (NGS). In addition to human and mouse cells, SCT’s technology can be applied to any host that concentrates plasma cells in lymphoid tissues. SCT integrates advances in multiple disciplines, such as wafer fabrication, molecular biology, precision mechanical engineering, nanotechnology, image processing, NGS, and bioinformatics. SCT’s approach substantially decreases the time and investment needed to discover high quality therapeutic and diagnostic antibodies.


This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The inclusion of forward-looking statements should not be regarded as a representation that either of the companies’ plans or objectives will be achieved. Forward-looking statements involve inherent risks and uncertainties and a number of important factors could cause actual results to differ materially from those contained in any such forward-looking statement. These factors include, but are not limited to, uncertainties associated with: drug development and regulatory review process, scientific discovery process, competition, pricing environment, financing, intellectual property, and the evolution of the market for innovative antibody discovery. The companies undertake no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.